| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLE |
Ligand Pharmaceuticals, Inc., San Diego, California 92121
Address all correspondence and requests for reprints to: Dr. Sha Liu, Ligand Pharmaceuticals, Inc., 10275 Science Center Drive, San Diego, California 92121. E-mail: . sliu{at}ligand.com
The retinoid X receptor (RXR) agonist bexarotene can cause clinically significant hypothyroidism in cutaneous T cell lymphoma patients. The mechanism by which the RXR agonist produces this effect is unclear. We have studied the impact of a selective RXR agonist (rexinoid), LG100268, on rat thyroid axis hormones and show that the acute phase of hypothyroidism is associated with reduced pituitary TSH secretion. A single oral administration of LG100268 to naive Sprague Dawley rats causes a rapid and statistically significant decline in TSH levels (apparent in 0.5–1 h). Total T4 and T3 levels decline more gradually, reaching statistical significance 24 h after treatment. Increasing doses of LG100268 produce greater suppression of thyroid axis hormones. To investigate the mechanism(s) mediating this suppression, we determined pituitary TSHß mRNA, TSH protein levels, and TRH-stimulated TSH secretion. Two hours after treatment, neither TSHß mRNA nor TSH protein levels were altered by LG100268. However, LG100268 treatment reduced the area under the curve for TRH-stimulated TSH secretion by 54%. We have identified an unexpected mechanism by which rexinoids induce hypothyroidism by acutely reducing TSH secretion from the anterior pituitary. This mechanism is independent of the rexinoid’s previously demonstrated inhibition of TSHß gene transcription.
This article has been cited by other articles:
 |
|
 |
|
  J. W. A. Smit, M. P. M. Stokkel, A. M. Pereira, J. A. Romijn, and T. J. Visser Bexarotene-Induced Hypothyroidism: Bexarotene Stimulates the Peripheral Metabolism of Thyroid Hormones J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2496 - 2499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Golden, K. B. Weber, T. L. Hernandez, S. I. Sherman, W. W. Woodmansee, and B. R. Haugen Single-Dose Rexinoid Rapidly and Specifically Suppresses Serum Thyrotropin in Normal Subjects J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 124 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Desvergne, L. Michalik, and W. Wahli Transcriptional Regulation of Metabolism Physiol Rev, April 1, 2006; 86(2): 465 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Sharma, W. R. Hays, W. M. Wood, U. Pugazhenthi, D. L. St. Germain, A. C. Bianco, W. Krezel, P. Chambon, and B. R. Haugen Effects of Rexinoids on Thyrotrope Function and the Hypothalamic-Pituitary-Thyroid Axis Endocrinology, March 1, 2006; 147(3): 1438 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Leibowitz, R. J. Ardecky, M. F. Boehm, C. L. Broderick, M. A. Carfagna, D. L. Crombie, J. D'Arrigo, G. J. Etgen, M. M. Faul, T. A. Grese, et al. Biological Characterization of a Heterodimer-Selective Retinoid X Receptor Modulator: Potential Benefits for the Treatment of Type 2 Diabetes Endocrinology, February 1, 2006; 147(2): 1044 - 1053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kanayama, N. Kobayashi, S. Mamiya, T. Nakanishi, and J.-i. Nishikawa Organotin Compounds Promote Adipocyte Differentiation as Agonists of the Peroxisome Proliferator-Activated Receptor {gamma}/Retinoid X Receptor Pathway Mol. Pharmacol., March 1, 2005; 67(3): 766 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Ogilvie, R. Saladin, T. R. Nagy, M. S. Urcan, R. A. Heyman, and M. D. Leibowitz Activation of the Retinoid X Receptor Suppresses Appetite in the Rat Endocrinology, February 1, 2004; 145(2): 565 - 573. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
